ReviewhLife2026
Engineering nasally delivered IgM antibodies for respiratory viral infections.
Review in hLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory viral infections remain a significant global health burden, requiring interventions that establish robust defense directly at the portal of entry. Intranasal delivery of engineered IgM antibodies represents a highly potent platform for achieving mucosal protection. In this review, we evaluate the structural and functional rationale for prioritizing engineered IgM antibodies for mucosal immunity, provide preclinical evidence of their efficacy against respiratory viruses, and critically analyze the biomanufacturing and formulation strategies necessary for clinical translation. While bivalent antibodies are highly susceptible to viral mutational escape, the avidity-driven affinity enhancement provided by IgM scaffolds enables superior cross-linking of virions. This effectively immobilizes antigenically drifted variants and facilitates rapid mucociliary clearance, demonstrating superior efficacy against respiratory pathogens compared to their parental IgG isotypes. Concurrently, emerging biomanufacturing, purification, and formulation strategies are successfully overcoming historical stability and production hurdles to enable clinical translation. By addressing these translational challenges, this review provides a comprehensive roadmap for developing engineered IgM into a robust, variant-agnostic mucosal defense strategy against emerging and reemerging respiratory threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.